The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.
Dr. Reardon on the Need for a New Standard of Care in GBMDecember 1st 2016
David A. Reardon, MD, clinical director at the Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the need for a new standard of care in the treatment landscape of glioblastoma multiforme.
IDO Inhibitors Among Immunotherapy Strategies Under Study in GlioblastomaNovember 30th 2016
The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.
Dr. Iavarone on the Role of the ID2 Protein in Brain CancerNovember 22nd 2016
Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.
Phase II Trial Looks to Study Optune's Efficacy in Grade III Recurrent Glioma
Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.
Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBMNovember 20th 2016
Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.
Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain CancerNovember 19th 2016
Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.
Optune Survival Benefit in GBM Sustained With Long-Term DataNovember 19th 2016
Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.
Checkpoint Inhibitors Show Promise in Glioblastoma
Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.
Adding Ibudilast to Temozolomide Increases Apoptosis, Survival in Preclinical GBM StudyNovember 18th 2016
Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.
Dr. van den Bent on Next Steps for ABT-414 in Brain CancerNovember 18th 2016
Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.
Dr. Perry on Implications of WHO Tumor Classifications in Brain CancerNovember 18th 2016
Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.
Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant DiseaseNovember 10th 2016
Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.